Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

Eakapol Wangkahart; Areerat Thongsrisuk; Regis Vialle; Sirinya Pholchamat; Phitcharat Sunthamala; Janjira Phudkliang; Prapansak Srisapoome; Tiehui Wang; Christopher J. Secombes

doi:10.1016/j.fsi.2023.108563

Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

Eakapol Wangkahart^* (Corresponding Author), Areerat Thongsrisuk, Regis Vialle, Sirinya Pholchamat, Phitcharat Sunthamala, Janjira Phudkliang, Prapansak Srisapoome, Tiehui Wang, Christopher J. Secombes

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Streptococcus agalactiae is regarded as a major bacterial pathogen of farmed fish, with outbreaks in Nile tilapia causing significant losses. Vaccination is considered the most suitable method for disease control in aquaculture, with the potential to prevent such outbreaks if highly efficacious vaccines are available for use. Several vaccines have been produced to protect against S. agalactiae infection in tilapia, including inactivated vaccines, live attenuated vaccines, and subunit vaccines, with variable levels of protection seen. Two commercial adjuvants, Montanide™ ISA 763 A VG and ISA 763 B VG, have been developed recently and designed to improve the safety and efficacy of oil-based emulsions delivered by intraperitoneal injection. In particular, their mode of action may help identify and stimulate particular immunological pathways linked to the intended protective response, which is an important tool for future vaccine development. Therefore, this study aimed to characterize the potential of two adjuvanted-bacterial vaccines against S. agalactiae (SAIV) comparatively, to determine their usefulness for improving protection and to analyse the immune mechanisms involved. Nile tilapia were divided into four groups: 1) fish injected with PBS as a control, 2) fish injected with the SAIV alone, 3) fish injected with the SAIV + Montanide™ ISA 763 A VG, and 4) fish injected with the SAIV + Montanide™ ISA 763 B VG. Following immunization selected innate immune parameters were analysed, including serum lysozyme, myeloperoxidase, and bactericidal activity, with significantly increased levels seen after immunization. Cytokines associated with innate and adaptive immunity were also studied, with expression levels of several genes showing significant up-regulation, indicating good induction of cell-mediated immune responses. Additionally, the specific IgM antibody response against S. agalactiae was determined and found to be significantly induced post-vaccination, with higher levels seen in the presence of the adjuvants. In comparison to the protection seen with the unadjuvanted vaccine (61.29% RPS), both Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG improved the RPS, to 77.42% and 74.19% respectively. In conclusion, Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG have shown potential for use as adjuvants for fish vaccines against streptococcosis, as evidenced by the enhanced immunoprotection seen when given in combination with the SAIV vaccine employed in this study.

Original language	English
Article number	108563
Journal	Fish & Shellfish Immunology
Volume	134
Early online date	27 Jan 2023
DOIs	https://doi.org/10.1016/j.fsi.2023.108563
Publication status	Published - Mar 2023

Bibliographical note

Acknowledgements
We are highly grateful to thank Seppic, France, for providing us with the commercial products of MontanideTM ISA 763A VG and MontanideTM 437 ISA 763B VG.

Funding
This research project was financially supported by Mahasarakham University (Grant No. 6517022

Data Availability Statement

The data that has been used is confidential.

Keywords

Immune response
Adjuvants
Montanide™ ISA 763A VG
Inactivated vaccine
Nile tilapia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.fsi.2023.108563Licence: Unspecified

Wangkahart_etal_FSI_Comparative_Study_Of_AAM
© 2023. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 1.81 MBLicence: CC BY-NC-ND

Cite this

Wangkahart, E., Thongsrisuk, A., Vialle, R., Pholchamat, S., Sunthamala, P., Phudkliang, J., Srisapoome, P., Wang, T., & Secombes, C. J. (2023). Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus). Fish & Shellfish Immunology, 134, Article 108563. https://doi.org/10.1016/j.fsi.2023.108563

Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus). / Wangkahart, Eakapol (Corresponding Author); Thongsrisuk, Areerat; Vialle, Regis et al.
In: Fish & Shellfish Immunology, Vol. 134, 108563, 03.2023.

Research output: Contribution to journal › Article › peer-review

Wangkahart, E, Thongsrisuk, A, Vialle, R, Pholchamat, S, Sunthamala, P, Phudkliang, J, Srisapoome, P, Wang, T & Secombes, CJ 2023, 'Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)', Fish & Shellfish Immunology, vol. 134, 108563. https://doi.org/10.1016/j.fsi.2023.108563

@article{e213d6a391424dcdad3e2932668a0b4c,

title = "Comparative study of the effects of Montanide{\texttrademark} ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)",

abstract = "Streptococcus agalactiae is regarded as a major bacterial pathogen of farmed fish, with outbreaks in Nile tilapia causing significant losses. Vaccination is considered the most suitable method for disease control in aquaculture, with the potential to prevent such outbreaks if highly efficacious vaccines are available for use. Several vaccines have been produced to protect against S. agalactiae infection in tilapia, including inactivated vaccines, live attenuated vaccines, and subunit vaccines, with variable levels of protection seen. Two commercial adjuvants, Montanide{\texttrademark} ISA 763 A VG and ISA 763 B VG, have been developed recently and designed to improve the safety and efficacy of oil-based emulsions delivered by intraperitoneal injection. In particular, their mode of action may help identify and stimulate particular immunological pathways linked to the intended protective response, which is an important tool for future vaccine development. Therefore, this study aimed to characterize the potential of two adjuvanted-bacterial vaccines against S. agalactiae (SAIV) comparatively, to determine their usefulness for improving protection and to analyse the immune mechanisms involved. Nile tilapia were divided into four groups: 1) fish injected with PBS as a control, 2) fish injected with the SAIV alone, 3) fish injected with the SAIV + Montanide{\texttrademark} ISA 763 A VG, and 4) fish injected with the SAIV + Montanide{\texttrademark} ISA 763 B VG. Following immunization selected innate immune parameters were analysed, including serum lysozyme, myeloperoxidase, and bactericidal activity, with significantly increased levels seen after immunization. Cytokines associated with innate and adaptive immunity were also studied, with expression levels of several genes showing significant up-regulation, indicating good induction of cell-mediated immune responses. Additionally, the specific IgM antibody response against S. agalactiae was determined and found to be significantly induced post-vaccination, with higher levels seen in the presence of the adjuvants. In comparison to the protection seen with the unadjuvanted vaccine (61.29% RPS), both Montanide{\texttrademark} ISA 763 A VG and Montanide{\texttrademark} ISA 763 B VG improved the RPS, to 77.42% and 74.19% respectively. In conclusion, Montanide{\texttrademark} ISA 763 A VG and Montanide{\texttrademark} ISA 763 B VG have shown potential for use as adjuvants for fish vaccines against streptococcosis, as evidenced by the enhanced immunoprotection seen when given in combination with the SAIV vaccine employed in this study.",

keywords = "Immune response, Adjuvants, Montanide{\texttrademark} ISA 763A VG, Inactivated vaccine, Nile tilapia",

author = "Eakapol Wangkahart and Areerat Thongsrisuk and Regis Vialle and Sirinya Pholchamat and Phitcharat Sunthamala and Janjira Phudkliang and Prapansak Srisapoome and Tiehui Wang and Secombes, {Christopher J.}",

note = " Acknowledgements We are highly grateful to thank Seppic, France, for providing us with the commercial products of MontanideTM ISA 763A VG and MontanideTM 437 ISA 763B VG. Funding This research project was financially supported by Mahasarakham University (Grant No. 6517022",

year = "2023",

month = mar,

doi = "10.1016/j.fsi.2023.108563",

language = "English",

volume = "134",

journal = "Fish & Shellfish Immunology",

issn = "1050-4648",

publisher = "ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

AU - Wangkahart, Eakapol

AU - Thongsrisuk, Areerat

AU - Vialle, Regis

AU - Pholchamat, Sirinya

AU - Sunthamala, Phitcharat

AU - Phudkliang, Janjira

AU - Srisapoome, Prapansak

AU - Wang, Tiehui

AU - Secombes, Christopher J.

N1 - Acknowledgements We are highly grateful to thank Seppic, France, for providing us with the commercial products of MontanideTM ISA 763A VG and MontanideTM 437 ISA 763B VG. Funding This research project was financially supported by Mahasarakham University (Grant No. 6517022

PY - 2023/3

Y1 - 2023/3

N2 - Streptococcus agalactiae is regarded as a major bacterial pathogen of farmed fish, with outbreaks in Nile tilapia causing significant losses. Vaccination is considered the most suitable method for disease control in aquaculture, with the potential to prevent such outbreaks if highly efficacious vaccines are available for use. Several vaccines have been produced to protect against S. agalactiae infection in tilapia, including inactivated vaccines, live attenuated vaccines, and subunit vaccines, with variable levels of protection seen. Two commercial adjuvants, Montanide™ ISA 763 A VG and ISA 763 B VG, have been developed recently and designed to improve the safety and efficacy of oil-based emulsions delivered by intraperitoneal injection. In particular, their mode of action may help identify and stimulate particular immunological pathways linked to the intended protective response, which is an important tool for future vaccine development. Therefore, this study aimed to characterize the potential of two adjuvanted-bacterial vaccines against S. agalactiae (SAIV) comparatively, to determine their usefulness for improving protection and to analyse the immune mechanisms involved. Nile tilapia were divided into four groups: 1) fish injected with PBS as a control, 2) fish injected with the SAIV alone, 3) fish injected with the SAIV + Montanide™ ISA 763 A VG, and 4) fish injected with the SAIV + Montanide™ ISA 763 B VG. Following immunization selected innate immune parameters were analysed, including serum lysozyme, myeloperoxidase, and bactericidal activity, with significantly increased levels seen after immunization. Cytokines associated with innate and adaptive immunity were also studied, with expression levels of several genes showing significant up-regulation, indicating good induction of cell-mediated immune responses. Additionally, the specific IgM antibody response against S. agalactiae was determined and found to be significantly induced post-vaccination, with higher levels seen in the presence of the adjuvants. In comparison to the protection seen with the unadjuvanted vaccine (61.29% RPS), both Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG improved the RPS, to 77.42% and 74.19% respectively. In conclusion, Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG have shown potential for use as adjuvants for fish vaccines against streptococcosis, as evidenced by the enhanced immunoprotection seen when given in combination with the SAIV vaccine employed in this study.

AB - Streptococcus agalactiae is regarded as a major bacterial pathogen of farmed fish, with outbreaks in Nile tilapia causing significant losses. Vaccination is considered the most suitable method for disease control in aquaculture, with the potential to prevent such outbreaks if highly efficacious vaccines are available for use. Several vaccines have been produced to protect against S. agalactiae infection in tilapia, including inactivated vaccines, live attenuated vaccines, and subunit vaccines, with variable levels of protection seen. Two commercial adjuvants, Montanide™ ISA 763 A VG and ISA 763 B VG, have been developed recently and designed to improve the safety and efficacy of oil-based emulsions delivered by intraperitoneal injection. In particular, their mode of action may help identify and stimulate particular immunological pathways linked to the intended protective response, which is an important tool for future vaccine development. Therefore, this study aimed to characterize the potential of two adjuvanted-bacterial vaccines against S. agalactiae (SAIV) comparatively, to determine their usefulness for improving protection and to analyse the immune mechanisms involved. Nile tilapia were divided into four groups: 1) fish injected with PBS as a control, 2) fish injected with the SAIV alone, 3) fish injected with the SAIV + Montanide™ ISA 763 A VG, and 4) fish injected with the SAIV + Montanide™ ISA 763 B VG. Following immunization selected innate immune parameters were analysed, including serum lysozyme, myeloperoxidase, and bactericidal activity, with significantly increased levels seen after immunization. Cytokines associated with innate and adaptive immunity were also studied, with expression levels of several genes showing significant up-regulation, indicating good induction of cell-mediated immune responses. Additionally, the specific IgM antibody response against S. agalactiae was determined and found to be significantly induced post-vaccination, with higher levels seen in the presence of the adjuvants. In comparison to the protection seen with the unadjuvanted vaccine (61.29% RPS), both Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG improved the RPS, to 77.42% and 74.19% respectively. In conclusion, Montanide™ ISA 763 A VG and Montanide™ ISA 763 B VG have shown potential for use as adjuvants for fish vaccines against streptococcosis, as evidenced by the enhanced immunoprotection seen when given in combination with the SAIV vaccine employed in this study.

KW - Immune response

KW - Adjuvants

KW - Montanide™ ISA 763A VG

KW - Inactivated vaccine

KW - Nile tilapia

U2 - 10.1016/j.fsi.2023.108563

DO - 10.1016/j.fsi.2023.108563

M3 - Article

SN - 1050-4648

VL - 134

JO - Fish & Shellfish Immunology

JF - Fish & Shellfish Immunology

M1 - 108563

ER -

Comparative study of the effects of Montanide™ ISA 763A VG and ISA 763B VG adjuvants on the immune response against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus)

Abstract

Bibliographical note

Data Availability Statement

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this